MMP9 and Familial prostate cancer: In pancreatic cancer, miR-301a may act as an oncogene by negatively regulating SAMD4 as its target [102], while in prostate cancer, miR-301a may be involved in metastasis through AR/TGF-β1/Smad/MMP9 signaling modulation [103].